Portal de Periódicos da CAPES

Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy

2008; American Society for Microbiology; Volume: 52; Issue: 4 Linguagem: Inglês

10.1128/aac.01301-07

1098-6596

Jade Ghosn, I. De Montgolfier, Chantal Cornélie, Stéphanie Dominguez, Claire Pérot, Gilles Peytavin, Anne‐Geneviève Marcelin, Michèle Pauchard, Zineb Ouagari, Manuela Bonmarchand, Rachid Agher, Vincent Cálvez, François Bricaire, Marc Dommergues, Christine Katlama, Roland Tubiana,

HIV-related health complications and treatments

We evaluated the safety and efficacy of a twice daily regimen containing 400 mg of indinavir and 100 mg of ritonavir in 32 human immunodeficiency virus (HIV)-infected women during pregnancy. The median indinavir trough concentration was 208 ng/ml during the third trimester. At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV.